


Leukaemia CARE

1, Birch Court
Blackpole East
Worcester
Worcestershire
WR3 8SG

Lori Farrar, Technology Appraisals Project Manager -National Institute for Health and Clinical Excellence Level 1A City Tower Piccadilly Plaza Manchester M1 4BD



28 June 2010


Re; - ACD ... Bortezomib and Thalidomide for the first-line treatment of myeloma

Dear Lori,

With reference to the above ACD - Leukaemia CARE fully endorses the response sent in by Myeloma UK.

We also welcome the provisional recommendations made by NICE and, like Myeloma UK, we consider them to be a sound and suitable basis for guidance in the NHS, and to be of significant benefit to myeloma patients.

Yours sincerely



Leukaemia CARE



